July 20, 2016
1 min read
Save

Half-dose or half-time PDT improves visual acuity, reduces subretinal fluid

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Half-dose and half-time fluorescein angiography-guided photodynamic therapy yielded similar visual and anatomic results in the treatment of central serous chorioretinopathy, a study found.

The retrospective case series included 61 eyes with acute or chronic central serous chorioretinopathy involving the fovea. Half-dose PDT was performed in 35 eyes, and half-time PDT was performed in 26 eyes.

The half-dose regimen comprised irradiance of 600 mW/cm2, laser time of 83 seconds and verteporfin 3 mg/m2. The half-time regimen comprised irradiance of 600 mW/cm2, laser time of 42 seconds and verteporfin 6 mg/m2.

Mean follow-up after PDT was 14.8 months.

Both groups had significant gains in best corrected visual acuity compared with baseline at 1, 3, 6 and 12 months. BCVA improved more in the half-dose PDT group than in the half-time PDT group at 1 month and 3 months but not at 6 months and 12 months.

No eyes in the half-time PDT group and one eye in the half-dose PDT group had a loss of BCVA.

Subretinal fluid resolved within 1 month in 60% of patients in the half-dose PDT group and 81% of patients in the half-time PDT group; the between-group difference was not statistically significant.

Fluid resolved completely in all patients in the half-time PDT group at 6 months. Fluid resolved completely in 32 of 35 patients in the half-dose PDT group at 12 months, with three patients lost to follow-up. Subretinal fluid resolved significantly faster in the half-time PDT group than in the half-dose PDT group (P = .024).

Central serous chorioretinopathy recurred in three eyes in the half-dose PDT group and two eyes in the half-time PDT group. Subretinal fluid resolved in all recurrent cases after re-treatment.

No systemic or treatment-related side effects were reported. by Matt Hasson

Disclosure: The authors report no relevant financial disclosures.